DeepMed Research

Clavis Pharma

🇳🇴Norway

Country: 🇳🇴Norway

Ownership: Private

Established: 2001-01-01

Employees: 11

Market Cap: -

Website: https://online-rezeptfrei.net/prednisolon-tabletten

Clinical Trials

Elacytarabine Mass Balance Study in Healthy Volunteers

Phase 1

Completed

Conditions: Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects

Interventions: Drug: [14C]-Elacytarabine

First Posted Date: 2013-02-05

Last Posted Date: 2013-08-28

Lead Sponsor: Clavis Pharma

Target Recruit Count: 6

Registration Number: NCT01783964

Locations: 🇬🇧
Quotient Clinical, Ruddington, Nottngham, United Kingdom

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

Phase 1

Completed

Conditions: Relapsed/Refractory AML

First Posted Date: 2010-12-13

Last Posted Date: 2013-09-23

Lead Sponsor: Clavis Pharma

Target Recruit Count: 43

Registration Number: NCT01258816

Locations: 🇪🇸
Hospital San Pedro Alcantara, Cáceres, Spain
🇪🇸
ICO - Hospital Duran i Reynals, Barcelona, Catalunya, Spain
🇬🇧
University Hospital of Wales, Cardiff, Cardiff, United Kingdom

and more 3 locations

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

Phase 3

Completed

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Elacytarabine
Drug: Investigator's Choice

First Posted Date: 2010-06-22

Last Posted Date: 2013-09-27

Lead Sponsor: Clavis Pharma

Target Recruit Count: 381

Registration Number: NCT01147939

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Winship Cancer Institute at Emory, Atlanta, Georgia, United States

and more 70 locations

A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Elacytarabine plus idarubicin

First Posted Date: 2009-12-18

Last Posted Date: 2013-09-27

Lead Sponsor: Clavis Pharma

Target Recruit Count: 51

Registration Number: NCT01035502

Locations: 🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇫🇷
CHU Lyon, Hospital Edouard Herriot, Lyon, France

and more 5 locations

A Study of CP-4126 in Patients With Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Advanced Adenocarcinoma of Pancreas

Interventions: Drug: IV CP-4126

First Posted Date: 2009-06-04

Last Posted Date: 2012-02-10

Lead Sponsor: Clavis Pharma

Target Recruit Count: 21

Registration Number: NCT00913198

Locations: 🇧🇪
Clinique d'Oncologie Médicale, Institut Jules Bordet, Brussels, Belgium
🇳🇴
Oslo University Hospital, Ullevål, Oslo, Norway
🇳🇴
Oslo University Hospital, The Norwegian Radium Hospital,, Oslo, Norway

A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: CP-4055

First Posted Date: 2009-01-29

Last Posted Date: 2013-09-13

Lead Sponsor: Clavis Pharma

Target Recruit Count: 28

Registration Number: NCT00831636

Locations: 🇮🇹
Medical Oncology, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy
🇮🇹
Department of Oncology, Catholic University of the Sacred Heart, Rome, Italy
🇧🇪
U.Z. Gasthuisberg, Gynecologic Oncology, Herestraat 49, Leuven, Belgium

and more 2 locations

A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: CP-4126
Drug: Gemcitabine

First Posted Date: 2008-10-23

Last Posted Date: 2010-09-06

Lead Sponsor: Clavis Pharma

Target Recruit Count: 26

Registration Number: NCT00778128

Locations: 🇧🇪
Institute Jules Bordet, Brussels, Belgium
🇳🇱
University Medical Centre Utrecht, Utrecht, Netherlands
🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Phase 2

Completed

Conditions: Malignant Melanoma

First Posted Date: 2007-07-10

Last Posted Date: 2013-09-12

Lead Sponsor: Clavis Pharma

Target Recruit Count: 18

Registration Number: NCT00498836

Locations: 🇸🇪
Umeå University Hospital, Umeå, Sweden
🇺🇸
Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas, United States
🇸🇪
Lund University Hospital, Lund, Sweden

and more 3 locations

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Advanced Colorectal Cancer
Colorectal Cancer

First Posted Date: 2007-07-10

Last Posted Date: 2009-06-04

Lead Sponsor: Clavis Pharma

Target Recruit Count: 16

Registration Number: NCT00498407

Locations: 🇬🇧
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧
Aberdeen Royal Infirmary, Foresterhill,, Aberdeen, United Kingdom
🇬🇧
Medical Oncology Dept. of Cancer Studies and Molecular Medicine, Leicester Royal Infirmary, Leicester, United Kingdom

and more 1 locations

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies
AML

Interventions: Drug: CP-4055

First Posted Date: 2006-11-30

Last Posted Date: 2013-09-18

Lead Sponsor: Clavis Pharma

Target Recruit Count: 153

Registration Number: NCT00405743

Locations: 🇺🇸
Mew York Medical College, Division of Oncology, Valhalla, New York, United States
🇺🇸
Duke University Medical Center (DUMC), Durham, North Carolina, United States
🇺🇸
Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd., San Antonio, Texas, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy